Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst

Key Points

• HC Wainwright cut its Q3 2026 EPS estimate to a loss of $0.61 from $0.36 and forecasts a full-year 2026 loss of $3.03 per share, indicating deeper expected losses.
• Vanda Pharmaceuticals recently missed quarterly expectations, reporting a $1.04-per-share loss versus the $0.58 consensus estimate and revenue of $50.53 million versus $61.92 million expected.
• Analyst sentiment remains mixed but leans positive: HC Wainwright maintained a Buy rating with a $20 target, while B. Riley kept its Buy rating but cut its target to $12 from $17; the consensus rating is Moderate Buy with a $13.70 target.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Research analysts at HC Wainwright dropped their Q3 2026 earnings estimates for shares of Vanda Pharmaceuticals in a report issued on Monday, August 10th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of ($0.61) for the quarter, down from their prior forecast of ($0.36). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is ($2.65) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals' Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($3.03) EPS, Q1 2027 earnings at ($0.41) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.18) EPS, Q4 2027 earnings at ($0.11) EPS and FY2027 earnings at ($0.94) EPS.

VNDA has been the topic of several other research reports. Wall Street Zen lowered Vanda Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Saturday, May 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a research report on Friday, July 17th. Finally, B. Riley Financial restated a "buy" rating and issued a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $13.70.

Vanda Pharmaceuticals Price Performance

VNDA stock opened at $4.93 on Wednesday. Vanda Pharmaceuticals has a 52-week low of $4.17 and a 52-week high of $9.94. The company has a quick ratio of 1.60, a current ratio of 1.61 and a debt-to-equity ratio of 0.01. The stock has a market cap of $298.07 million, a price-to-earnings ratio of -1.06 and a beta of 0.64. The business has a fifty day moving average of $5.73 and a two-hundred day moving average of $6.71.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.46). The business had revenue of $50.53 million during the quarter, compared to analyst estimates of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VNDA. Torren Management LLC purchased a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth $25,000. Russell Investments Group Ltd. raised its holdings in shares of Vanda Pharmaceuticals by 456.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 5,328 shares during the period. Allworth Financial LP purchased a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter valued at $43,000. Caitong International Asset Management Co. Ltd lifted its stake in Vanda Pharmaceuticals by 3,010.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 10,389 shares of the biopharmaceutical company's stock worth $92,000 after acquiring an additional 10,055 shares in the last quarter. Finally, Jain Global LLC acquired a new position in Vanda Pharmaceuticals during the 4th quarter worth about $94,000. Hedge funds and other institutional investors own 88.14% of the company's stock.

Vanda Pharmaceuticals News Summary

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Analysts retain bullish ratings: HC Wainwright maintained a Buy rating and a $20 price target, while B. Riley Financial reiterated its Buy recommendation. These targets imply substantial potential upside from VNDA’s recent $4.93 level. B. Riley Financial Reiterates Buy Rating for Vanda Pharmaceuticals
• Positive Sentiment: Psoriasis pipeline remains an area of investor interest: Vanda was included among psoriasis drug companies to watch during Psoriasis Awareness Month, highlighting potential opportunities from its development programs. Psoriasis Drug Stocks to Watch
• Neutral Sentiment: Short-interest data provides no meaningful signal: Reported short interest was zero shares, with a zero-day days-to-cover ratio. The figures suggest little measurable short-selling activity, but the reported percentage change is not meaningful because the comparison balance was also zero.
• Negative Sentiment: HC Wainwright significantly lowered its earnings outlook: The firm cut its FY2026 EPS estimate to -$3.03 from -$1.98 and its FY2027 forecast to -$0.94 from -$0.36. Quarterly estimates were also reduced, including Q3 2026 to -$0.61 and Q4 2026 to -$0.57. The revisions point to deeper and more prolonged losses than previously expected.
• Negative Sentiment: B. Riley reduced its price target: Although the firm kept its Buy rating, it lowered the target to $12 from $17, signaling less confidence in near-term valuation. The estimate cuts add to concerns following Vanda’s recent quarterly loss and revenue miss.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company's research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda's mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda's flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source